Core Viewpoint - The company, Guoshengtang, demonstrates strong resilience in performance growth, with a projected revenue increase in the second quarter of 2025 surpassing that of the first quarter due to rapid store expansion and a stable policy environment [1][2]. Group 1: Performance and Growth - In Q1 2025, Guoshengtang's offline patient visits increased by 12.7% year-on-year, showing a month-on-month acceleration trend [1]. - The company plans to open 15-20 new stores in 2025, including self-built and acquired locations, and aims to enter 2-3 new cities [1]. - Guoshengtang's revenue growth in the second half of 2025 is expected to exceed that of the first half due to base effects [1]. Group 2: Technological Advancements - On June 7, 2025, Guoshengtang launched the first national AI digital twin of a traditional Chinese medicine (TCM) expert, Professor Li Hao, which utilizes deep learning from over 40 years of clinical experience [2]. - The company plans to release 20 AI digital twins of renowned doctors in 2025 to enhance overall diagnostic quality and address the shortage of quality TCM resources [2]. - A partnership with Huawei was established in May 2025 to promote AI technology applications in the TCM field [2]. Group 3: Financial Returns and Shareholder Value - In 2024, Guoshengtang returned a total of 420 million yuan to investors through dividends and buybacks, equivalent to 137% of the company's net profit for that year [3]. - As of June 25, 2025, the company has repurchased approximately 85 million HKD worth of shares, representing 1.1% of the total share capital at the beginning of the year [3]. - The company is expected to continue rewarding shareholders through dividends and buybacks due to strong profitability and cash flow [3].
固生堂(2273.HK)：收入增长快速复苏 门店扩张提速